Brief: Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer
10/04/2025 12:12
April 10 (Reuters) - Pasithea Therapeutics Corp KTTA.O: PASITHEA THERAPEUTICS ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE (SRC) RECOMMENDATION FROM ITS ONGOING PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER PASITHEA THERAPEUTICS CORP - NO DOSE-LIMITING TOXICITIES (DLT'S) OR RASH OBSERVED TO DATE PASITHEA THERAPEUTICS CORP - SRC RECOMMENDED THAT TRIAL ESCALATE TO NEXT DOSE LEVEL OF 30MG CAPSULE Source text: ID:nGNX9HpRyQ Further company coverage: KTTA.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement